Other languages Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
1.39 ^USD	-4.14%		-0.71%	+243.38%

Jul. 01	Nexalin Technology Completes $5.3 Million Share Offering	MT
Jun. 28	Top Midday Decliners	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Nexalin Technology Completes $5.3 Million Share Offering	Jul. 01
Top Midday Decliners	Jun. 28
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	Jun. 28
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell	Jun. 28
Top Premarket Decliners	Jun. 28
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal	Jun. 26
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 MA Neurostimulation Device by the Brazilian Health Regulatory Agency	Jun. 18
Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device	Jun. 03
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	Apr. 25
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	Apr. 09
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board	Apr. 02
Top Midday Gainers	Mar. 28
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	Mar. 28
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman	Mar. 14
Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia	Mar. 06
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device	Feb. 08
Nexalin Technology, Inc. Unveils Gen-3 HALO?? Clarity 15 Milliamp Neurostimulation Device	Jan. 11
Nexalin Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Other languages

Filters